Assignee
TUOJIE BIOTECH SHANGHAI CO LTD
CN·1 granted patent·15 pending applications·0 citations·filing 2019–2023
Top patents by PatentIndex Score
16 records- 0155US2024229037A1SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATETUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0254US2024376101A1Substituted 1,4-dihydro-1,6-naphthyridine amide and use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0354US2025332190A1Lpa-targeting sirna and conjugateTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0453US2026076990A1Dsrna, use thereof and preparation method thereforTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 0553US2023287418A1Modified sirna with reduced off-target activityTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0652US2024209004A1BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITORTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0751US2025042847A1Substituted phenylpropionic acid derivative and use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0850US2024391895A1Pyridazine-containing compound and medicinal use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0949US2023250095A1Benzimidazole derivatives, preparation method therefor and medical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1048US2025197853A1Sirna targeting angiotensinogen and pharmaceutical use of sirnaTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1146US2024317725A1Lpa1 small molecule antagonistTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1245US2023405138A1Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1343US2024140963A1Fused tricyclic cyclin-dependent kinase inhibitor, and preparation method therefor and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1440US2022380385A1Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
- 1537US2022073521A1Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2019·Application pending·0 cites
- 1631US12365730B2Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2020·Granted Jul 22, 2025·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when TUOJIE BIOTECH SHANGHAI CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →